Tjalf Ziemssen
← Back to Technische Universität Dresden
Technische Universität Dresden
Tjalf Ziemssen works in Multiple Sclerosis Research Studies, Polyomavirus and related diseases, Chronic Lymphocytic Leukemia Research, Psoriasis: Treatment and Pathogenesis, Health Systems, Economic Evaluations, Quality of Life. Recorded institutional associations include University Hospital Carl Gustav Carus, Centre for Tactile Internet with Human-in-the-Loop, Technische Universität Dresden.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
2018 · 937 citationsIdentifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
2012 · 612 citationsAssociation of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
2019 · 546 citationsStroke-Induced Immunodepression
2007 · 473 citationsNeurofilaments as biomarkers in neurological disorders — towards clinical application
2024 · 446 citationsEffector T-cell trafficking between the leptomeninges and the cerebrospinal fluid
2016 · 370 citationsEffect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
2018 · 333 citationsThe role of TH17 cells in multiple sclerosis: Therapeutic implications
2020 · 302 citationsSafety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
2017 · 273 citationsDigital Twins for Multiple Sclerosis
2021 · 272 citationsGlatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
2002 · 268 citationsSiponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
2013 · 234 citationsMolecular biomarkers in multiple sclerosis
2019 · 228 citationsSpectral Analysis of Heart Rate Variability: Time Window Matters
2019 · 215 citationsNon-motor dysfunction in Parkinson's disease
2007 · 205 citationsMultiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
2021 · 191 citationsOptimizing treatment success in multiple sclerosis
2015 · 190 citationsThe Activation Status of Neuroantigen-specific T Cells in the Target Organ Determines the Clinical Outcome of Autoimmune Encephalomyelitis
2004 · 188 citationsImpaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation
2016 · 180 citationsClinical outcome measures in multiple sclerosis: A review
2020 · 177 citationsThe Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
2019 · 174 citationsA self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity
2017 · 173 citationsGlatiramer acetate: Mechanisms of action in multiple sclerosis
2007 · 168 citationsTreatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
2017 · 164 citationsMultiple sclerosis beyond EDSS: depression and fatigue
2009 · 160 citations